Brief: Biocartis Ups FY Cash Position Target To Around EUR 120 Mln

Biocartis NV

12/11/2020 06:36

Nov 12 (Reuters) - Biocartis Group NV  BCART.BR :
    * END OF Q3 2020, BIOCARTIS' CASH POSITION AMOUNTED TO EUR
137
MILLION (UNAUDITED FIGURE)
    * TARGETING A YEAR-OVER-YEAR COMMERCIAL VOLUME GROWTH AROUND
30%,
REPRESENTING A VOLUME OF IDYLLA CARTRIDGES AROUND 228K
    * TARGETING AN INSTALLED BASE GROWTH AROUND 300 NEW IDYLLA
INSTRUMENT PLACEMENTS
    * EMERGENCY USE AUTHORIZATION ('EUA') WITH US FDA OF IDYLLA
SARS-COV-2 TEST IS PENDING
    * US FDA REGULATORY PROCESS, LED BY IMMUNEXPRESS, IS ONGOING
FOR
SEPTICYTE RAPID ON IDYLLA
    * TARGETED CASH POSITION IN RANGE OF EUR 120 MILLION BY 2020
YEAR-END, AN INCREASE OF EUR 10M FROM PREVIOUS GUIDANCE

Source text for Eikon:  ID:nGNE7x5lgz 
Further company coverage:  BCART.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))